The STAR Prospective Clinical Series

Completed

Conditions studied: Metastasis to Vertebral Column

In brief

Prospective clinical series to gather post tumor ablation clinical outcomes from subjects with painful spinal metastases following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.

Key facts

Study ID

NCT02217150

Run by

DFINE Inc.

People needed

50

Starts

2013-06-01

Expected to finish

2016-04-01

Last updated by the study team

2017-01-20

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The STAR™ Tumor Ablation System is indicated for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body.

You may not qualify if…

• The device is contraindicated in subjects with heart pacemakers, or other electronic device implants.
• The device is contraindicated in vertebral body levels C1-7.

Where it is running

• Palomar Pomerado Health System — Escondido, California, United States
• University of Southern California — Los Angeles, California, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Suburban Hospital — Bethesda, Maryland, United States
• Austin Radiological Associates — Austin, Texas, United States
• St. Mark's Hospital — Salt Lake City, Utah, United States
• Inova Alexandria Hospital — Alexandria, Virginia, United States
• Providence Sacred Heart Hospital — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.